A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis

Inclusion Criteria:The investigator thinks that the subject can continue to benefit from participating in the extension trial;Fully understand the extension trial and sign the informed consent form;Complete the ZGJAK025 trial for 16 weeks and have good compliance;It is expected that the time interval between the first administration and the last administration of ZGJAK025 trial for the subject should be ≤ 4 weeks;Exclusion Criteria:Within 4 weeks before enrollment, there were any adverse events ≥ 3 levels related to the test drug that did not return to level 1 or normal;The investigator thinks that the subject is not suitable for the trial.